
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Lupin's Somerset, NJ facility, inspected by the FDA from May 7 to May 17, 2024, received Form-483 with six observations. The company's Q4 FY24 saw a 41.38% net profit drop to ₹359.43 crore on a 3.64% revenue decline to ₹4895.11 crore.
Lupin Limited, a pharmaceutical company known for its innovation, underwent a pre-approval inspection by the US Food and Drug Administration (FDA) at its manufacturing facility in Somerset, New Jersey.
Explore: Lupin Limited Share Price
The inspection was carried out from May 7 to May 17, 2024, and resulted in the issuance of a Form-483 by the FDA. This form highlighted six observations made by the inspectors regarding potential regulatory violations.
Lupin promptly responded to the FDA's observations, pledging to address them comprehensively. As per regulatory requirements, the company will provide a detailed corrective action plan within the specified timeframe to ensure compliance with FDA regulations.
Additional Read: Share Market News
In the fourth quarter of FY24, Lupin witnessed a significant decline in its consolidated net profit, plummeting by 41.38% to ₹359.43 crore. Additionally, the company's revenue from operations saw a decrease of 3.64% to ₹4895.11 crore compared to Q4 FY23.
Lupin disclosed the outcome of the FDA inspection in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This communication was made to the Bombay Stock Exchange (BSE), ensuring transparency and adherence to regulatory norms.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading